Mannkind Corporation: Diabetes Mellitus trials

The registry lists 33 Diabetes Mellitus studies with Mannkind Corporation as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 6Phase 2 11Phase 3 9Phase 4 3No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesRecruitingNCT07224321Phase 2
• Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesCompletedNCT05243628Phase 4Results posted
• Afrezza® Dosing Optimization StudyCompletedNCT04849845Phase 4Results posted
• Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsCompletedNCT02527265Phase 2Results posted
• Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusCompletedNCT01451398Phase 3Results posted
• An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' TrialCompletedNCT00754624Phase 2Results posted
• Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate IntakeTerminatedNCT00747006Phase 2Results posted
• A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin LisproCompletedNCT00662857Phase 2Results posted
• Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseTerminatedNCT00642616Phase 3Results posted
• Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 DiabetesCompletedNCT00332488Phase 3Results posted
• Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upCompletedNCT00309244Phase 3Results posted
• Safety of Inhaled Insulin With Type 1 and Type 2 DiabetesCompletedNCT00308737Phase 3Results posted
• Efficacy & Safety of Inhaled Insulin in Type 1 DiabetesCompletedNCT00308308Phase 3Results posted
• INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesCompletedNCT05904743Phase 4
• Afrezza® INHALE-1 Study in PediatricsCompletedNCT04974528Phase 3
• PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)CompletedNCT02485327Phase 1
• Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes MellitusCompletedNCT02470637Phase 1
• Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation PowderNo longer availableNCT01798914
• Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 DiabetesCompletedNCT01544881Phase 1
• Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166TerminatedNCT01201928
• Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 DiabetesCompletedNCT00934414Phase 2
• A 2-Month Safety Follow-Up TrialCompletedNCT00741429
• A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy VolunteersCompletedNCT00674050Phase 1
• Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal ChallengeCompletedNCT00642681
• A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedNCT00642538Phase 1
• Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes MellitusCompletedNCT00539890Phase 3
• A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin GlargineCompletedNCT00539396Phase 2
• 18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 DiabetesCompletedNCT00511732Phase 2
• Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 DiabetesCompletedNCT00511719Phase 2
• Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 DiabetesCompletedNCT00511602Phase 2
• A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesCompletedNCT00475371Phase 1
• To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.CompletedNCT00419302Phase 2
• Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and AsthmaTerminatedNCT00332826Phase 3